Joaquin Duato
Johnson & Johnson’s chairman and CEO since 2022, a 35-year company veteran who split off the consumer-health business to focus on pharmaceuticals and medtech.
Pay vs performance
what happened while he earned itNo score, no opinion. Compensation is filed; stock and S&P are market returns over the window shown; revenue and EPS are latest reported vs the prior year. You decide.
Why this pay?
- His fiscal 2025 pay was $32.8 million, up about 30% and pushed past the $30 million mark partly by a $5.3 million change-in-pension-value line that reflects interest-rate and actuarial swings rather than new cash or stock. The widely cited ~$27 million figure is J&J’s "total direct compensation" measure, not the proxy’s SCT total.
Worth knowing
Johnson & Johnson has raised its dividend for more than 60 consecutive years — a “Dividend King” that has increased its payout through every recession since the 1960s.
Source: Company filings · More facts →
Quick facts
Compensation breakdown
DEF 14AThe ~$27M figure often quoted is J&J’s "total direct compensation," not the SCT. The $5.3M pension line is an actuarial change, not cash. Source: Johnson & Johnson 2026 Proxy (FY2025) →
Compensation history
salary + cash vs stock, from the proxiesRelated intelligence
every filing on Johnson & Johnson, one hop awayCareer
Compare pay with
Every figure ties to a filing. Compensation is the total from Johnson & Johnson's Summary Compensation Table for FY2025(grant-date values, which can differ from what an executive realizes when awards vest). We publish what the filings say, and we don't grade people. Photo: Stephanie Diani / CC BY-SA 4.0 / Wikimedia Commons.